Search

Your search keyword '"Ostor, Andrew"' showing total 235 results
Start Over Author "Ostor, Andrew"
235 results on '"Ostor, Andrew"'

7. Efficacy and Safety of the TYK2/JAK1 Inhibitor Brepocitinib for Active Psoriatic Arthritis: A Phase IIb Randomized Controlled Trial

Author

Mease, Philip, primary, Helliwell, Philip, additional, Silwinska‐Stanczyk, Paula, additional, Miakisz, Malgorzata, additional, Ostor, Andrew, additional, Peeva, Elena, additional, Vincent, Michael S., additional, Sun, Qiankun, additional, Sikirica, Vanja, additional, Winnette, Randall, additional, Qiu, Ruolun, additional, Li, Gang, additional, Feng, Gang, additional, Beebe, Jean S., additional, and Martin, David A., additional

Published
2023
Full Text
View/download PDF

8. P134 Efficacy of Upadacitinib on Psoriatic Arthritis with Axial Involvement Defined by Investigator Assessment and PRO-Based Criteria: Results from two Phase 3 Studies

Author

Baraliakos, Xenofon, primary, Ranza, Roberto, additional, Ostor, Andrew, additional, Ciccia, Francesco, additional, Coates, Laura C, additional, Rednic, Simona, additional, Walsh, Jessica, additional, Gao, Tianming, additional, Lertratanakul, Apinya, additional, Song, In-Ho, additional, Fabiana Ganz, Fabiana, additional, Douglas, Kevin, additional, and Deodhar, Atul, additional

Published
2023
Full Text
View/download PDF

10. 33236 Impact of risankizumab on improving symptoms and health-related quality of life and reducing fatigue and pain among psoriatic arthritis patients with moderate-to-severe skin involvement: Evidence from 2 phase III trials

Author

Papp, Kim, primary, Soliman, Ahmed M., additional, Kaufmann, Christian, additional, Barcomb, Lisa, additional, Wang, Zailong, additional, White, Douglas, additional, Ostor, Andrew, additional, and Kristensen, Lars Erik, additional

Published
2022
Full Text
View/download PDF

14. Effect of upadacitinib on reducing pain in patients with active psoriatic arthritis or ankylosing spondylitis: post hoc analysis of three randomised clinical trials

Author

McInnes, Iain B, primary, Ostor, Andrew J K, additional, Mease, Philip J, additional, Tillett, William, additional, Baraliakos, Xenofon, additional, de Vlam, Kurt, additional, Bessette, Louis, additional, Lippe, Ralph, additional, Maniccia, Anna, additional, Feng, Dai, additional, Gao, Tianming, additional, Zueger, Patrick, additional, Saffore, Christopher, additional, Kato, Koji, additional, Song, In-Ho, additional, and Deodhar, Atul, additional

Published
2022
Full Text
View/download PDF

16. Biological Therapies for Rheumatoid Arthritis: An Overview for the Clinician

Author

Findeisen,Kate E, Sewell,Julia, and Ostor,Andrew JK

Subjects
Targets and Therapy [Biologics]
Abstract

Kate E Findeisen,1,* Julia Sewell,1,* Andrew JK Ostor2,3 1The Alfred Hospital, Melbourne, Victoria, Australia; 2Cabrini Medical Centre, Melbourne, Victoria, Australia; 3Monash University, Melbourne, Victoria, Australia*These authors contributed equally to this workCorrespondence: Andrew JK OstorCabrini Medical Centre, Melbourne, Victoria, AustraliaTel +61 3 9509 4244Email andrewostor@gmail.comAbstract: Rheumatoid arthritis (RA) is a disease characterised by inflammation of synovial joints and poses a substantial healthcare burden on both the individual and society. One of the most significant shifts in the RA therapeutic landscape has occurred with the introduction of biological disease modifying anti-rheumatic drugs (bDMARDs). There are five classes of bDMARDs currently available, each with a different molecular target and subtle differences in their efficacy and safety profile. This review also describes the “real-world” use of bDMARDs and how they fit into the overall RA treatment guidelines.Keywords: rheumatoid arthritis, biological therapies, bDMARDs

Published
2021

18. Safety and Efficacy of Upadacitinib in Patients With Active Ankylosing Spondylitis and an Inadequate Response to Nonsteroidal Antiinflammatory Drug Therapy: One‐Year Results of a Double‐Blind, Placebo‐Controlled Study and Open‐Label Extension

Author

Deodhar, Atul, primary, Heijde, Désirée, additional, Sieper, Joachim, additional, Van den Bosch, Filip, additional, Maksymowych, Walter P., additional, Kim, Tae‐Hwan, additional, Kishimoto, Mitsumasa, additional, Ostor, Andrew, additional, Combe, Bernard, additional, Sui, Yunxia, additional, Chu, Alvina D., additional, and Song, In‐Ho, additional

Published
2021
Full Text
View/download PDF

19. Upadacitinib improves patient-reported outcomes vs placebo or adalimumab in patients with rheumatoid arthritis: results from SELECT-COMPARE.

Author

UCL - SSS/IREC/RUMA - Pôle de Pathologies rhumatismales, UCL - (SLuc) Service de rhumatologie, Strand, Vibeke, Tundia, Namita, Bergman, Martin, Ostor, Andrew, Durez, Patrick, Song, In-Ho, Enejosa, Jeffrey, Schlacher, Casey, Song, Yan, Fleischmann, Roy, UCL - SSS/IREC/RUMA - Pôle de Pathologies rhumatismales, UCL - (SLuc) Service de rhumatologie, Strand, Vibeke, Tundia, Namita, Bergman, Martin, Ostor, Andrew, Durez, Patrick, Song, In-Ho, Enejosa, Jeffrey, Schlacher, Casey, Song, Yan, and Fleischmann, Roy

Abstract

To evaluate the impact of upadacitinib vs placebo and adalimumab treatment, on patient-reported outcomes (PROs) in SELECT-COMPARE in an active RA population with inadequate responses to MTX (MTX-IR). PROs in patients receiving upadacitinib (15 mg QD), placebo, or adalimumab (40 mg EOW) while on background MTX were evaluated over 48 weeks. PROs included Patient Global Assessment of Disease Activity (PtGA) and pain by visual analogue scale (VAS), the HAQ Disability Index (HAQ-DI), the 36-Item Short Form Survey (SF-36), morning (AM) stiffness duration and severity, the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F), and work instability. Least squares mean (LSM) changes and proportions of patients reporting improvements ≥ minimal clinically important differences (MCIDs) and scores ≥ normative values were evaluated. Upadacitinib and adalimumab resulted in greater LSM changes from baseline vs placebo across all PROs (P < 0.05) at week 12, and pain and AM stiffness severity (P < 0.05) at week 2. More upadacitinib- vs placebo-treated (P < 0.05) and similar percentages of upadacitinib- vs adalimumab-treated patients reported improvements ≥ MCID across all PROs at week 12. Upadacitinib vs adalimumab resulted in greater LSM changes from baseline in PtGA, pain, HAQ-DI, stiffness severity, FACIT-F, and the SF-36 Physical Component Summary (PCS) (all P < 0.05) at week 12. More upadacitinib- vs adalimumab-treated patients reported scores ≥ normative values in HAQ-DI and SF-36 PCS (P < 0.05) at week 12. More upadacitinib- vs adalimumab-treated patients maintained clinically meaningful improvements in PtGA, pain, HAQ-DI, FACIT-F, and AM stiffness through 48 weeks. In MTX-IR patients with RA, treatment with upadacitinib resulted in statistically significant and clinically meaningful improvements in PROs equivalent to or greater than with adalimumab. ClinicalTrials.gov, http://clinicaltrials.gov, NCT02629159.

Published
2021

31. Early diagnosis crucial in ankylosing spondylitis

Author

Malaviya, Anshuman P. and Ostor, Andrew J.K.

Subjects
Antirheumatic agents, Ankylosing spondylitis -- Diagnosis, Backache -- Diagnosis, Health, Health care industry
Abstract

Why is early diagnosis so Important? How should diagnosis be confirmed? What are the evidence-based treatment options? BACK PAIN IS COMMON WITH UP TO 9% OF THE POPULATION CONSULTING THEIR [...]

Published
2011

35. Disease remission the goal of therapy in rheumatoid arthritis

Author

Nisar, Muhammad K. and Ostor, Andrew J.K.

Subjects
Rheumatoid factor -- Health aspects, Antirheumatic agents -- Health aspects, Arthritis -- Care and treatment -- Development and progression -- Health aspects, Rheumatoid arthritis -- Care and treatment -- Development and progression -- Health aspects, Physicians (General practice) -- Health aspects, Health, Health care industry
Abstract

Why is early diagnosis important? How should RA be classified? Why should patients be treated to target? RHEUMATOID ARTHRITIS WAS PREVIOUSLY CONSIDERED A SEVERE SYSTEMIC DISEASE leading to inexorable decline. [...]

Published
2010

36. Diagnosing joint pain in older people

Author

Bhagat, Shweta and Ostor, Andrew J.K.

Subjects
Aged -- Health aspects, Joint diseases -- Diagnosis -- Care and treatment, Health, Health care industry
Abstract

What are the most common causes? How should patients be diagnosed? What are the treatment options? * MUSCULOSKELETAL DISEASE IS THE MOST COMMON CAUSE OF CHRONIC PAIN AND disability in [...]

Published
2010

37. Safety and Efficacy of Upadacitinib in Patients With Active Ankylosing Spondylitis and an Inadequate Response to Nonsteroidal Antiinflammatory Drug Therapy: One‐Year Results of a Double‐Blind, Placebo‐Controlled Study and Open‐Label Extension

Author

Deodhar, Atul, van der Heijde, Désirée, Sieper, Joachim, Van den Bosch, Filip, Maksymowych, Walter P., Kim, Tae‐Hwan, Kishimoto, Mitsumasa, Ostor, Andrew, Combe, Bernard, Sui, Yunxia, Chu, Alvina D., and Song, In‐Ho

Subjects
ANKYLOSING spondylitis, NONSTEROIDAL anti-inflammatory agents, JANUS kinases, TREATMENT effectiveness, RANDOMIZED controlled trials, BLIND experiment, DESCRIPTIVE statistics, NEUROTRANSMITTER uptake inhibitors, STATISTICAL sampling, ADVERSE health care events, PHARMACODYNAMICS
Abstract

Objective: To report the efficacy and safety of upadacitinib through 1 year in patients with ankylosing spondylitis (AS). Methods: In the SELECT‐AXIS 1 study, adults with active AS and an inadequate response to nonsteroidal antiinflammatory drugs were randomized to receive upadacitinib 15 mg once daily or placebo. At week 14, patients who had been randomized to receive placebo were switched to upadacitinib, and all patients continued in the open‐label extension and received upadacitinib up to week 104; interim data up to week 64 are reported herein. Results: Of 187 patients, 178 completed week 14 on study drug and entered the open‐label extension. Similar proportions of patients in either group (continuous upadacitinib or placebo‐to‐upadacitinib) achieved Assessment of SpondyloArthritis international Society 40% response (ASAS40) or Ankylosing Spondylitis Disease Activity Score (ASDAS) showing low disease activity at week 64: ≥70% of patients achieved these end points based on nonresponder imputation (NRI) and ≥81% based on as‐observed analyses. Furthermore, ≥34% (NRI) and ≥39% (as‐observed analysis) achieved ASDAS showing inactive disease or ASAS showing partial remission at week 64. Mean changes from baseline (week 0) to week 64 in pain, function, and inflammation showed consistent improvement or sustained maintenance through the study. Among 182 patients receiving upadacitinib (237.6 patient‐years), 618 adverse events (260.1 per 100 patient‐years) were reported. No serious infections, major adverse cardiovascular events, venous thromboembolic events, gastrointestinal perforation, or deaths were reported. Conclusion: Upadacitinib 15 mg once daily showed sustained and consistent efficacy over 1 year. Patients who switched from placebo to upadacitinib at week 14 showed similar efficacy versus those who received continuous upadacitinib. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

39. Early intervention is key in juvenile idiopathic arthritis

Author

Shaikh, Maliha F. and Ostor, Andrew J.K.

Subjects
Children -- Diseases, Antirheumatic agents, Arthritis -- Care and treatment, Evidence-based medicine, Health, Health care industry, Diseases, Care and treatment
Abstract

How should children be examined? What investigations should be carried out? What are the evidence-based treatment options? [FIGURE 1 OMITTED] JUVENILE IDIOPATHIC ARTHRITIS (JIA) IS ONE OF THE MOST COMMON [...]

Published
2009

40. Tight control in rheumatoid arthritis improves outcomes

Author

Ostor, Andrew J.K. and Conaghan, Philip G.

Subjects
American College of Rheumatology, Medicine -- Practice, Rheumatoid factor, Antirheumatic agents, Arthritis -- Patient outcomes -- Care and treatment, Rheumatoid arthritis -- Patient outcomes -- Care and treatment, Physicians (General practice), Health, Health care industry, Diseases, Care and treatment, Patient outcomes
Abstract

[FIGURE 1 OMITTED] How should rheumatoid arthritis be diagnosed? When is aggressive treatment justified? Which patients need urgent specialist assessment? THE MANAGEMENT OF RHEUMATOID ARTHRITIS (RA) HAS UNDERGONE MAJOR changes [...]

Published
2009

47. Presence of active gelatinases in endometrial carcinoma and correlation of matrix metalloproteinase expression with increasing tumor grade and invasion

Author

Di Nezza, Lisa A., Misajon, Aileen, Zhang, Jin, Jobling, Tom, Quinn, Michael A., Ostor, Andrew G., Nie, Guiying, Salamonsen, Lois A., and Lopata, Alex

Subjects
Medical research -- Analysis, Cancer -- Research, Endometrial hyperplasia -- Research, Metalloenzymes -- Genetic aspects, Gene expression -- Physiological aspects, Colloids in medicine -- Physiological aspects, Cells -- Genetic aspects, Health
Published
2002

50. Upadacitinib Versus Placebo or Adalimumab in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results of a Phase III , Double‐Blind, Randomized Controlled Trial

Author

Fleischmann, Roy, primary, Pangan, Aileen L., additional, Song, In‐Ho, additional, Mysler, Eduardo, additional, Bessette, Louis, additional, Peterfy, Charles, additional, Durez, Patrick, additional, Ostor, Andrew J., additional, Li, Yihan, additional, Zhou, Yijie, additional, Othman, Ahmed A., additional, and Genovese, Mark C., additional

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results